undamentalytics Newsletter
Sign in

Intellia Therapeutics, Inc. cash flow statement

In fiscal 2025, Intellia Therapeutics, Inc.'s operations generated −$395m of cash; it spent $1.1m on capital projects, leaving free cash flow of −$396m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations36−65−61−103−50−225−333−394−349−395−347
Depreciation and amortisation1346678910109
Stock-based pay71517152047911341548068
Capital spending610674131414612
Free cash flow30−75−68−110−53−238−347−408−355−396−349
Free cash flow after stock pay23−91−85−125−73−285−438−542−509−476−417
Shares issued1711412972—1,818—120177128—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: FENC vs NTLAIVVD vs NTLACUVL vs NTLA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Intellia Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Intellia Therapeutics, Inc.